Bioray Pharmaceutical Co., Ltd.

This early-stage study tests a new drug, BRY812, in 164 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug every three w…

This early-stage trial is testing a new drug, BR111, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug might slow or shrink tum…